摘要
AIM: To review previous studies(the last 6 years) about the Helicobacter pylori(H. pylori) antibiotic resistance in order to evaluate the trend in antibiotic resistance. METHODS: In this study, the Pub Med, MEDLINE, Science Direct, Google Scholar and Scielo manuscripts were reviewed from 2009 to 2014. RESULTS: On the whole rates of H. pylori antibiotic resistance were 47.22%(30.5%-75.02%) for metronidazole, 19.74%(5.46%-30.8%) for clarithromycin, 18.94%(14.19%-25.28%) for levofloxacin, and 14.67%(2%-40.87%) for amoxicillin, 11.70%(0%-50%) for tetracycline, 11.5%(0%-23%) for furazolidon and 6.75%(1%-12.45%) for rifabutin. The frequency of tetracycline, metronidazole and amoxicillin resistance was higher in Africa, while clarithromycin and levofloxacin resistance was higher in North America and Asian, respectively. CONCLUSION: The most sensitive drug is rifabutin and the lowest sensitive drug is metronidazole in the world. The worldwide H. pylori antibiotic resistance to clarithromycin and levofloxacin has increased during the last 6 years. The present systematic review show alarming results and a novel plan is needed for eradication therapy of H. pylori infections.
AIM： To review previous studies （the last 6 years） about the Helicobacter pylori （H. pylori ） antibiotic resistance in order to evaluate the trend in antibiotic resistance. METHODS： In this study, the PubMed, MEDLINE, Science Direct, Google Scholar and Scielo manuscripts were reviewed from 2009 to 2014. RESULTS： On the whole rates of H. pylori antibiotic resistance were 47.22% （30.5%-75.02%） for metroni-dazole, 19.74% （5.46%-30.8%） for clarithromycin, 18.94% （14.19%-25.28%） for levofoxacin, and 14.67% （2%-40.87%） for amoxicillin, 11.70% （0%-50%） for tetracycline, 11.5% （0%-23%） for furazolidon and 6.75% （1%-12.45%） for rifabutin. The frequency of tetracycline, metronidazole and amoxicillin resistance was higher in Africa, while clarithromycin and levoflo-xacin resistance was higher in North America and Asian, respectively.CONCLUSION： The most sensitive drug is rifabutin and the lowest sensitive drug is metronidazole in the world. The worldwide H. pylori antibiotic resistance to clarithromycin and levofoxacin has increased during the last 6 years. The present systematic review show alarming results and a novel plan is needed for eradication therapy of H. pylori infections.
